FDA approves Novo Nordisk's long-awaited diabetes drug Print E-mail
By Staff and Wire Reports   
Saturday, 26 September 2015 10:42
The U.S. Food and Drug Administration on Friday approved Danish drugmaker Novo Nordisk's diabetes drug Tresiba, two years after rejecting the long-acting form of insulin.
The regulator also approved the company's Ryzodeg, an injection that combines Tresiba and a fast-acting manmade form of insulin.
   
The FDA approved the drugs with a warning that they should not be used in patients who have high levels of the chemical ketone. (http://1.usa.gov/1MOio9w)
   
Novo Nordisk, the world's largest diabetes drugs maker, separately said it expects to launch Tresiba in the United States during the first quarter of 2016.
   
Analysts were confident that the FDA would approve Tresiba, considered as a future blockbuster for the company.
   
The FDA had declined approval in 2013, asking for more data on risks of heart problems from using the drugs. 
   
   



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 

Newsletter